JHH1_LIVER
HCC · Hepatocellular Carcinoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
- subtype
- —
- cancer_type
- HCC
- ccle_sample_id
- JHH1_LIVER
- synthetic_from_ccle
- true
- display_name
- JHH-1
- ccle_lineage
- liver
- ccle_lineage_subtype
- hepatocellular_carcinoma
- oncotree_code
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.290
- ESTROGEN_RESPONSE_LATE+0.237
- P53_PATHWAY+0.221
- CHOLESTEROL_HOMEOSTASIS+0.220
- ANGIOGENESIS+0.212
- MYOGENESIS+0.199
- HYPOXIA+0.183
- APICAL_SURFACE+0.176
- GLYCOLYSIS+0.144
- PROTEIN_SECRETION+0.132
Top 10 suppressed
- MYC_TARGETS_V2-0.501
- E2F_TARGETS-0.372
- G2M_CHECKPOINT-0.370
- MYC_TARGETS_V1-0.361
- INTERFERON_ALPHA_RESPONSE-0.307
- INTERFERON_GAMMA_RESPONSE-0.297
- PANCREAS_BETA_CELLS-0.214
- ALLOGRAFT_REJECTION-0.154
- MTORC1_SIGNALING-0.137
- HEDGEHOG_SIGNALING-0.112
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-00551 | — | cohortA1 | 0.763 |
| 2 | TCGA-A8-A06P-01A-11R-A00Z-07 | — | A | 0.751 |
| 3 | SRR8613707 | — | C | 0.743 |
| 4 | 20040084.LumA | — | A | 0.738 |
| 5 | BS_GV3NZ9QD | Ependymoma NOS | — | 0.715 |
| 6 | 4df6c488-ef2f-4019-a1b0-3a3624039be8 | — | — | 0.715 |
| 7 | 35c6ff25-753c-4ebe-bbe7-2e7105d052e8 | — | — | 0.703 |
| 8 | 80ff3d8c-da3f-4a1f-822c-c6132e2b0574 | — | — | 0.697 |
| 9 | SRR8518453 | — | F | 0.696 |
| 10 | TCGA-D8-A146-01A-31R-A115-07 | — | A | 0.696 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.237 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.221 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.212 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.199 | Inavolisib | — uncovered |
| HYPOXIA | 0.183 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.176 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.144 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.132 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.132 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.111 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.104 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.082 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.081 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.068 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.064 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.060 | Inavolisib | — uncovered |
| COMPLEMENT | 0.058 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |